|
Program |
|
“Economics-Based Reimbursement Policies: Enhanced Efficiency, But an
Impediment to Innovation?" |
|
| |
Sunday, 3 November 2002 |
|
12.00-13.00 |
Exhibits & Poster Presentations – Session I
|
| |
Willem Burger
Foyer & Expo Hal |
|
13.00-15.00 |
Welcome from the ISPOR President
Willem Burger Zaal C3.2 |
| |
Peter Davey MD, FRCP, 2002-2003 ISPOR President & Head of
Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK
Introduction and Congress Objectives
Frans Rutten PhD, Congress Chair and Professor of Health Economics,
Erasmus University, Rotterdam, The Netherlands
First Plenary Session
|
The Societal Benefits and Costs of the 4th Hurdle: The European
Experience |
| Moderator:
Bengt Jönsson, Professor, Stockholm School of Economics, Stockholm,
Sweden |
The Government’s
Perspective
Speaker: Léon J S Wever LLM, Director,
Department of Pharmaceutical Affairs and Medical Technology, Ministry of
Health, The Hague, The Netherlands
The Pharmaceutical Industry’s Perspective
Speaker: Mark Ratcliffe PhD, Director,
European Health Outcomes Research, Eli Lilly & Co Ltd, Windlesham, UK
| This
presentation will cover the following issues: |
| • |
The key objective and
rationale for conducting HTA is efficiency. |
| • |
HTA investment decisions
might be far from optimal. |
| • |
The lack of
well-integrated systems for HTA with delivery and financing of health
care lead to a risk of inefficient
and sub-optimal resource allocation. |
| • |
The industry is a major
supplier of technology evaluations. |
| • |
HTA is a potential
cost-driver for industry, patients, government and society.
|
Evidence of the Impact on the Pharmaceutical Industry
Speaker: C. Daniel Mullins PhD, Associate
Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA
This presentation will provide a brief overview of how the 4th hurdle has
impacted the pharmaceutical industry differently across countries. Empirical
observations and anecdotes, as well as economic theory, will be presented to
explain the impact of the 4th hurdle on the pharmaceutical industry. Using
game theory, the potential for sub-optimal investment in pharmacoeconomics
by the pharmaceutical industry will be explored through a theoretical
application of the prisoner’s dilemma model. The presentation will conclude
with hypothetical example for calculating the monetary impact of the 4th
hurdle impact on the pharmaceutical industry.
Panel Discussion
|
|
15.00-15.30 |
Break |
|
15.30-17.00 |
ISPOR FORUMS |
|
15.30-17.00
|
Quality of Life Forum
Van Beuningen Zaal C3.5 |
| |
Summary
Measures of Population Health Status – World Health Organization Initiatives
This Forum is coordinated by the ISPOR Quality of Life Special Interest
Group (http://www.ispor.org/sigs/sigsindex.asp)
Measuring health outcomes is a key component in establishing the
cost-effectiveness of any new therapy as well as the measurement of
population health. The World Health Organization (WHO) has setup new
programmes to describe and value health/health-related quality of life (HRQOL)
for the evaluation of healthcare. This work and the implications for
government health agencies, the pharmaceutical industry and the wider
research community will be discussed.
Moderator: Paul Kind Mphil, Senior
Research Fellow, University of York, Centre for Health Economics, York, UK
Policy Implications of using Population Health Measures
Speaker: Pennifer Erickson PhD, Co-founder,
O.L.G.A., State College, PA, USA
The growing use of health status and quality-of-life measures has opened the
potential for better information for managing patient care and setting
health policy. This presentation will introduce the Health Outcomes
Framework for combining population health information at the macro level
with research and clinical practice data collection activities at the micro
level. This integration of clinical and population health data is essential
for equity in health.
The World Health Organization Measurement of
Population Health Initiative
Speaker: Christopher J.L. Murray MD, PhD,
Executive Director, Evidence and Information for Policy, World Health
Organization, Geneva, Switzerland
Using Population Health Status Measures in
Clinical Studies: Informational and International Implications
Speaker: Diane Jacqueline Wild MSc, Partner,
Oxford Outcomes, Oxford, UKOver the
last thirty years significant progress has been made in the development of
instruments to assess the health status of populations. This presentation
will address some of the issues surrounding the use of these instruments in
clinical studies and the importance of cultural validity from an
international perspective.
Panel and Audience Discussions
|
|
15.30-17.00 |
Medical
Device & Diagnostics Forum
Van Rijckevorsel Zaal C4.5 |
| |
Basing Medical Devices and Diagnostic Reimbursement Policies on
Economic and Clinical Information: How to Incorporate Total Healthcare Costs
and Outcomes
This Forum is coordinated by the ISPOR European Medical Device and
Diagnostics Council (http://www.ispor.org/committees/advcouncils.asp).
Moderator:Markus Siebert MSc, Business Area
Director - Economic Affairs, Eucomed, Brussels, Belgium
Total Healthcare Costs And Outcomes: Thoughts On
The 5th And 6th Hurdle On The Way To Coverage Of Medical Technology
Speaker: Rod Taylor PhD, Department of Public
Health and Epidemiology, The University of Birmingham, Birmingham, UK
Systematic Assessment Of Health Technologies,
Outcomes Research, And Technological Competitiveness: A Conceptual Model For
Transparent "Rules Of The Game" As A Basis For Reimbursement Policies In
Health Care Systems
Speaker: Dr. Jose A Valverde, Director,
Agencia de Evaluacion de Tecnologias Sanitarias de Andalucia (Spanish Agency
for Health Technology Assessment), Seville, Spain
The Impact Of ‘Silo’ Budgets On Health System
Performance: The Industry Experience
Speaker: Arne Heissel PhD, Health
Outcomes Manager-Europe, Ethicon Endo-Surgery, Norderstedt, Germany and
Brigitte Casteels, Therapy Access Manager-Neurological Division, Medtronic
Europe SA, Suisse, Belgium
|
|
15.30-17.00 |
Central & Eastern European
Forum Plate
Zaal C4.4 |
| |
The Methods of Drug Reimbursement in Central and Eastern European
Countries
This Forum is coordinated by the ISPOR Central & Eastern European Special
Interest Group
http://www.ispor.org/sigs/sigsindex.asp
Moderator: Pawel Sztwiertnia, Chair, ISPOR
Polish Chapter and Deputy Director, Public Sector Financing Department,
Ministry of Finance, Warsaw, Poland
Speakers from 6 Central and Eastern European countries will describe the
system of drug reimbursement in his/her country: What is the legal
framework? Who makes the decision on reimbursement? What are the criteria
for reimbursement? What is the method/system for drug reimbursement? What is
the role of pharmacoeconomics in reimbursement decisions? Is the
pharmacoeconomic analysis a mandatory part of the reimbursement application?
Are there official guidelines for pharmacoeconomic analysis? Are there any
guidelines? What are the drug reimbursement expenditures (public, private,
total) and trends?
|
|
15.30-17.00 |
Advisory Council Forum
Willem Burger Zaal C3.2 |
| |
Incorporating Total Healthcare Costs and Outcomes in Drug Reimbursement
Policies in Europe
This Forum is coordinated by the ISPOR Institutional Council Commissioned
Paper Task Force.
Moderator: Adrian Towse MA, Mphil, Director,
Office of Health Economics, London, UK
Speakers: Alistair McGuire, City University
London, London, UK; Vittorio Mapelli, Istituto di Economia Sanitaria, Milan,
Italy; Fernando Antonanzas Villar, Universidad de la Rioja, Logroño, Spain;
Marc Koopmanschap PhD, Erasmus University, Rotterdam, The Netherlands;
Wolfgang Greiner PhD, University of Hannover, Hannover, Germany;
J.-Matthias Graf von der Schulenburg PhD, University of Hannover, Hannover,
Germany; Claude Le Pen PhD, CLP Sante, Paris, France
ISPOR is sponsoring the development of papers from United Kingdom, Germany,
France, The Netherlands, Italy, and Spain to explore the efficiency with
which these major European countries use pharmaceuticals, focusing on the
incentives in the budgeting process for drugs and health care overall, and
looking at reform proposals. These papers are to describe the current drug
reimbursement system for each country, impact of budget system on rates of
diffusion of health technologies with examples, and discuss proposed
government reform or improvements or reform that should be proposed. These
papers will be discussed during this forum.
|
|
17.00-19.00 |
Exhibitors’ Open House, Poster
Presentations – Session I
Willem Burger Foyer & Expo Hal |
| |
Sponsored by
Aegisnet |
|
19.00-20.00 |
Student Welcome Reception
Van Beuningen Zaal C3.5 |
| |
Introduction to Student Network
Zeba M Khan RPh, PhD, ISPOR Student Network Advisor & Senior Manager,
GlaxoSmithKline, Research Triangle Park, NC, USA and
Cher Beilfuss PharmD, 2002-2003 ISPOR Student Network & Student Council,
Chair, and Pfizer Inc. Pharmacoeconomics and Outcomes Research Fellow,
University of Michigan, Ann Arbor, MI, USA
|
|
